Intensity Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0
I'm LongbridgeAI, I can summarize articles.Revenue: As of FY2026 Q1, the actual value is USD 0.
EPS: As of FY2026 Q1, the actual value is USD -0.96, beating the estimate of USD -1.1067.
EBIT: As of FY2026 Q1, the actual value is USD -2.62 M.
Financial Performance for Three Months Ended March 31, 2026
Net Loss
Intensity Therapeutics, Inc. reported a net loss of - $2.4 million for the three months ended March 31, 2026, which is an improvement compared to a net loss of - $3.3 million for the same period in 2025.
Loss from Operations
The loss from operations was - $2.526 million for the three months ended March 31, 2026, compared to - $3.394 million for the same period in 2025.
Operating Expenses
Research and Development Expenses
Research and Development expenses were $1.2 million for the three months ended March 31, 2026, decreasing from $2.2 million for the same period in 2025, primarily due to lower INVINCIBLE-3 Study costs.
General and Administrative Expenses
General and Administrative expenses increased to $1.3 million for the three months ended March 31, 2026, from $1.2 million for the same period in 2025, mainly due to an estimated bonus accrual in 2026, partially offset by lower stock-based compensation and one-time expenses related to a reverse stock split.
Total Operating Expenses
Total operating expenses were $2.526 million for the three months ended March 31, 2026, down from $3.394 million for the same period in 2025.
Other Financial Items
Interest Income
Interest income significantly increased to $94 thousand for the three months ended March 31, 2026, from $15 thousand in the prior year period.
Other (Expense) Income, Net
This category showed a net expense of - $2 thousand for the three months ended March 31, 2026, compared to a net income of $32 thousand for the same period in 2025.
Balance Sheet Highlights
Cash and Cash Equivalents
As of March 31, 2026, cash and cash equivalents totaled $10.2 million, a decrease from $11.921 million as of December 31, 2025.
Total Current Assets
Total current assets were $10.906 million as of March 31, 2026, down from $12.709 million as of December 31, 2025.
Total Liabilities
Total liabilities increased slightly to $2.312 million as of March 31, 2026, from $2.225 million as of December 31, 2025.
Operational Metrics and Outlook
INVINCIBLE-4 Study (Triple Negative Breast Cancer)
Preliminary observations from the INVINCIBLE-4 Study showed that 71.4% (5 out of 7) of patients in Cohort A (receiving INT230-6 prior to standard of care) achieved a pathological complete response (pCR), compared to 33% (2 out of 6) in Cohort B (standard of care alone). Cohort A also experienced 44% fewer grade 3 or higher adverse events than Cohort B.
INVINCIBLE-3 Study (Soft Tissue Sarcoma)
Intensity Therapeutics, Inc. plans to resume enrollment in a limited number of U.S. sites for the INVINCIBLE-3 Study by the third quarter of 2026, with full patient enrollment and site activations prioritized once sufficient incremental funding is obtained.
Outlook Summary
Intensity Therapeutics, Inc. plans to resume enrollment for the INVINCIBLE-4 Study in the second quarter of 2026, with initiation of enrollment in France expected in the second or third quarter of 2026, and for the INVINCIBLE-3 Study in limited U.S. sites by the third quarter of 2026, prioritizing full enrollment upon sufficient funding. More detailed results for INVINCIBLE-4 Cohort A are anticipated at a future oncology conference. The company also intends to judiciously manage its cash burn.